Distinct Mitral Valve Proteomic Profiles in Rheumatic Heart Disease and Myxomatous Degeneration

Overview

Journal Clin Med Insights Cardiol

Publisher Sage Publications

Specialty Cardiology & Vascular Diseases

Date 2014 Sep 19

PMID 25232280

Citations 11

Authors

Carlo de Oliveira Martins

Keity Souza Santos

Frederico Moraes Ferreira

Priscila Camillo Teixeira

Pablo Maria Alberto Pomerantzeff

Carlos Ma Brandao

Roney Orismar Sampaio

Guilherme S Spina

Jorge Kalil

Luiza Guilherme

Edecio Cunha-Neto

Affiliations

Soon will be listed here.

Abstract

Rheumatic heart disease (RHD) affects heart-valve tissue and is the most serious consequence of group A Streptococcus infection. Myxomatous degeneration (MXD) is the most frequent valvopathy in the western world. In the present work, key protein expression alterations in the heart-valve tissue of RHD and MXD patients were identified and characterized, with controls from cadaveric organ donors. Proteins were separated by two-dimensional (2D)-electrophoresis and identified by mass spectrometry. We found 17 differentially expressed protein spots, as compared to control samples. We observed an increased expression of ASAP-2 in the RHD patients' valves, while collagen-VI, haptoglobin-related protein, prolargin, and cartilage oligomeric protein showed reduced expression. Valve tissue of MXD patients, on the other hand, presented lower expression of annexin-A1 and A2, septin-2, SOD (Cu/Zn), and transgelin. Tissue samples from both valvopathies displayed higher expression of apolipoprotein-A1. Biglycan was downexpressed in both diseases. Vimentin and lumican showed higher expression in RHD and lower in MXD. These results suggest that key pathogenetic mechanisms are intrinsically distinct in RHD and MXD.

Citing Articles

A study protocol to characterise pathophysiological and molecular markers of rheumatic heart disease and degenerative aortic stenosis using multiparametric cardiovascular imaging and multiomics techniques.

Mutithu D, Aremu O, Mokaila D, Bana T, Familusi M, Taylor L PLoS One. 2024; 19(5):e0303496.

PMID: 38739622 PMC: 11090351. DOI: 10.1371/journal.pone.0303496.

Serum Proteomic Profiles Reflect the Stages of Myxomatous Mitral Valve Disease in Dogs.

Resetar Maslov D, Farkas V, Rubic I, Kules J, Beletic A, Ljubic B Int J Mol Sci. 2023; 24(8).

PMID: 37108311 PMC: 10138901. DOI: 10.3390/ijms24087142.

Alpha-1-antitrypsin in serum exosomes and pericardial fluid exosomes is associated with severity of rheumatic heart disease.

Sharma S, Sarkar S, Choudhury C, Singh L, Singh H, Chakraborti A Mol Cell Biochem. 2022; 478(6):1383-1396.

PMID: 36318408 DOI: 10.1007/s11010-022-04595-x.

An Untargeted LC-MS based approach for identification of altered metabolites in blood plasma of rheumatic heart disease patients.

Das S, Kumar Y, Sharma S, Ray R, Arava S, Seth S Sci Rep. 2022; 12(1):5238.

PMID: 35347173 PMC: 8960827. DOI: 10.1038/s41598-022-09191-z.

Histopathological Characterization of Mitral Valvular Lesions from Patients with Rheumatic Heart Disease.

Gomes N, Pascoal-Xavier M, S A Passos L, Paula T, Aguiar J, Guarconi F Arq Bras Cardiol. 2021; 116(3):404-412.

PMID: 33909767 PMC: 8159546. DOI: 10.36660/abc.20200154.

References

Dolhnikoff M, Morin J, Roughley P, Ludwig M . Expression of lumican in human lungs. Am J Respir Cell Mol Biol. 1998; 19(4):582-7. DOI: 10.1165/ajrcmb.19.4.2979. View

Caira F, Stock S, Gleason T, McGee E, Huang J, Bonow R . Human degenerative valve disease is associated with up-regulation of low-density lipoprotein receptor-related protein 5 receptor-mediated bone formation. J Am Coll Cardiol. 2006; 47(8):1707-12. PMC: 3951851. DOI: 10.1016/j.jacc.2006.02.040. View

Grover J, Chen X, Korenberg J, Roughley P . The human lumican gene. Organization, chromosomal location, and expression in articular cartilage. J Biol Chem. 1995; 270(37):21942-9. DOI: 10.1074/jbc.270.37.21942. View

Hocking A, Shinomura T, McQuillan D . Leucine-rich repeat glycoproteins of the extracellular matrix. Matrix Biol. 1998; 17(1):1-19. DOI: 10.1016/s0945-053x(98)90121-4. View

Guilherme L, Kohler K, Kalil J . Rheumatic heart disease: mediation by complex immune events. Adv Clin Chem. 2011; 53:31-50. View

Guilherme L, Kohler K, Postol E, Kalil J . Genes, autoimmunity and pathogenesis of rheumatic heart disease. Ann Pediatr Cardiol. 2011; 4(1):13-21. PMC: 3104525. DOI: 10.4103/0974-2069.79617. View

Iozzo R . The family of the small leucine-rich proteoglycans: key regulators of matrix assembly and cellular growth. Crit Rev Biochem Mol Biol. 1997; 32(2):141-74. DOI: 10.3109/10409239709108551. View

Kuo H, Maslen C, Keene D, Glanville R . Type VI collagen anchors endothelial basement membranes by interacting with type IV collagen. J Biol Chem. 1997; 272(42):26522-9. DOI: 10.1074/jbc.272.42.26522. View

Cunningham M . Pathogenesis of group A streptococcal infections. Clin Microbiol Rev. 2000; 13(3):470-511. PMC: 88944. DOI: 10.1128/CMR.13.3.470. View

10.

Funderburgh J, Funderburgh M, Mann M, Conrad G . Arterial lumican. Properties of a corneal-type keratan sulfate proteoglycan from bovine aorta. J Biol Chem. 1991; 266(36):24773-7. View

11.

Reilly J, Nash J . Vitronectin (serum spreading factor): its localisation in normal and fibrotic tissue. J Clin Pathol. 1988; 41(12):1269-72. PMC: 1141758. DOI: 10.1136/jcp.41.12.1269. View

12.

Carapetis J, Steer A, Mulholland E, Weber M . The global burden of group A streptococcal diseases. Lancet Infect Dis. 2005; 5(11):685-94. DOI: 10.1016/S1473-3099(05)70267-X. View

13.

Mahimkar R, Nguyen A, Mann M, Yeh C, Zhu B, Karliner J . Cardiac transgenic matrix metalloproteinase-2 expression induces myxomatous valve degeneration: a potential model of mitral valve prolapse disease. Cardiovasc Pathol. 2008; 18(5):253-61. PMC: 3367668. DOI: 10.1016/j.carpath.2008.08.001. View

14.

Shoeman R, Hartig R, Traub P . Characterization of the nucleic acid binding region of the intermediate filament protein vimentin by fluorescence polarization. Biochemistry. 1999; 38(51):16802-9. DOI: 10.1021/bi991654r. View

15.

Yin Z, Jones G, Towns 2nd W, Zhang X, Abel E, Binkley P . Heart-specific ablation of Prkar1a causes failure of heart development and myxomagenesis. Circulation. 2008; 117(11):1414-22. DOI: 10.1161/CIRCULATIONAHA.107.759233. View

16.

Kojima S, Itoh Y, Matsumoto S, Masuho Y, Seiki M . Membrane-type 6 matrix metalloproteinase (MT6-MMP, MMP-25) is the second glycosyl-phosphatidyl inositol (GPI)-anchored MMP. FEBS Lett. 2000; 480(2-3):142-6. DOI: 10.1016/s0014-5793(00)01919-0. View

17.

Kim L, Kim D, Yang W, Shin D, Jung I, Park H . Overexpression of transforming growth factor-beta 1 in the valvular fibrosis of chronic rheumatic heart disease. J Korean Med Sci. 2008; 23(1):41-8. PMC: 2526480. DOI: 10.3346/jkms.2008.23.1.41. View

18.

Vuillermoz B, Khoruzhenko A, DOnofrio M, Ramont L, Venteo L, Perreau C . The small leucine-rich proteoglycan lumican inhibits melanoma progression. Exp Cell Res. 2004; 296(2):294-306. DOI: 10.1016/j.yexcr.2004.02.005. View

19.

Perkins D, Pappin D, Creasy D, Cottrell J . Probability-based protein identification by searching sequence databases using mass spectrometry data. Electrophoresis. 1999; 20(18):3551-67. DOI: 10.1002/(SICI)1522-2683(19991201)20:18<3551::AID-ELPS3551>3.0.CO;2-2. View

20.

Guirguis N, Abdel Alim M, Kotby A, Kotb M . Preferential recognition of human myocardial antigens by T lymphocytes from rheumatic heart disease patients. Infect Immun. 1997; 65(6):2197-205. PMC: 175303. DOI: 10.1128/iai.65.6.2197-2205.1997. View